Clinical Trials Logo

Clinical Trial Summary

Endoscopic retrograde cholangio pancreatography procedure will performed as per local standard procedure.After common bile duct cannulation,cholangiography will be performed (to confirm the stricture) followed by biliary sphincterotomy. All biliary strictures(Bismuth Type I/II/III/IV) will be enrolled for the study. Patient opting for Uncovered self expandable metallic stent / Plastic stent will undergo biliary stent placement and considered under control arm Patient opting for radio frequency ablation + Uncovered SEMS/Plastic stent will undergo radio frequency ablation and biliary stent placement and considered under Study arm The RFA probe will be inserted into the bile duct alongwith the guidewire. Keeping the electrode overlapping the stricture, RFA will be performed using a power of 10W for 120 seconds. The electrode will be kept at the ablation site for an additional 1 minute to allow the RFA probe to cool before removal to prevent thermal injury of normal tissue and/or endoscope accessory channel. If the stricture is more than 3 cm, step-by-step RFA will be performed from the superior to inferior aspect. After RFA application, an uncovered SEMS/Plastic stent will be placed.


Clinical Trial Description

Placement of self expandable metallic stent is the standard of care in the palliative management of patients with malignant biliary strictures . Relieves biliary obstruction and jaundice. Self expandable metallic stent provide efficient drainage and have superior patency rates compared with the plastic stents Endoscopic radio frequency ablation combined with stent placement can significantly prolong survival and the stent patency period without increasing the incidence of adverse events in patients with extra hepatic cholangiocarcinoma patient. Compared to plastic/ metal stent placement alone the addition of radio frequency ablation to stent placement would have better outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05320328
Study type Observational
Source Asian Institute of Gastroenterology, India
Contact Sai Dr Kumar, MBBS MD
Phone 9121792373
Email saiaig21@gmail.com
Status Recruiting
Phase
Start date June 10, 2021
Completion date December 10, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05600803 - Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions
Recruiting NCT05286814 - M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT06115655 - A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles
Enrolling by invitation NCT03951324 - Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study
Active, not recruiting NCT05374122 - AI Guidance for Biopsy in Suspected Cholangiocarcinoma N/A
Terminated NCT04276090 - Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma N/A
Completed NCT01232101 - Covered or Uncovered Bile Duct Stents N/A
Active, not recruiting NCT00582647 - Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Recruiting NCT00915863 - Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy N/A
Recruiting NCT05172310 - PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI Phase 1
Completed NCT01845337 - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Phase 2
Completed NCT04847167 - Mechanistic Loop Resolution Strategy for Short-type Single Balloon Enteroscopy N/A
Completed NCT00634751 - CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma Phase 1/Phase 2
Not yet recruiting NCT03838913 - Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB)